Accessibility links
One Year Later A commentary from Jeff Getty, a man who has AIDS. One year ago, he was given a baboon marrow transplant in an attempt to restore his immune system. He is doing well, but Getty complains about a sense that the company Glaxo-Wellcome is keeping the AIDS drug 15-92 off the market because it wants to maximize its profits for the old AIDS drug AZT. Getty also says he thinks there has been a whole bureaucracy built up around AIDS, with people making six-figure salaries. In the meantime, those with the disease are dying.

All Things Considered

One Year Later

Heard on All Things Considered

One Year Later

Listen · 4:20
  • Download
  • <iframe src="https://www.npr.org/player/embed/1057810/57810" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

A commentary from Jeff Getty, a man who has AIDS. One year ago, he was given a baboon marrow transplant in an attempt to restore his immune system. He is doing well, but Getty complains about a sense that the company Glaxo-Wellcome is keeping the AIDS drug 15-92 off the market because it wants to maximize its profits for the old AIDS drug AZT. Getty also says he thinks there has been a whole bureaucracy built up around AIDS, with people making six-figure salaries. In the meantime, those with the disease are dying.